Aprea reports Q3 2026 results and updates APR-1051 trial
Aprea reported $37.8M in cash and expanded its WEE1 inhibitor trials, with cash runway extending into early 2028. Updated Phase 1 data is set for presentation at EORTC-NCI-AACR Symposium in November 2026.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed